Latest Ratios: P/E Ratio -2.6x · EV/EBITDA N/A · ROE -366.3%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $54M | $71M | $18M | $5M | $27M | $215M | $379M | — | — | — | — |
| Enterprise Value | $51M | $67M | $12M | $12M | $32M | $205M | $375M | — | — | — | — |
| P/E Ratio → | -2.55 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 7.94 | 6.47 | 2.34 | — | 4.65 | 5.98 | 5.21 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -366.3% | -366.3% | -1038.7% | -1278.6% | -189.2% | -74.9% | -68.1% | -22.3% | — | — | — |
| ROA | -143.8% | -143.8% | -143.0% | -115.4% | -112.6% | -67.8% | -64.5% | -28.6% | 31.6% | -258.1% | -104.9% |
| ROIC | -547.8% | -547.8% | -733.2% | -227.4% | -157.0% | -68.4% | -41.3% | — | — | — | — |
| ROCE | -243.2% | -243.2% | -271.8% | -179.3% | -145.2% | -79.1% | -50.4% | -88.4% | -120.8% | -74.3% | -111.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 1.25 | — | 2.36 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.33 | -0.78 | — | 0.89 | -0.27 | -0.06 | -0.13 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -48.87 | -48.87 | -18.00 | -12.91 | -28.45 | — | -2168.76 | -459.33 | 141.88 | -3404.50 | -104.48 |
Net cash position: cash ($6M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.97 | 1.97 | 1.31 | 0.83 | 1.66 | 4.31 | 16.41 | 10.63 | 2.18 | 5.57 | 10.75 |
| Quick Ratio | 1.82 | 1.82 | 1.31 | 0.83 | 1.66 | 4.31 | 16.41 | 10.49 | 2.18 | 5.57 | 10.75 |
| Cash Ratio | 1.67 | 1.67 | 1.23 | 0.77 | 1.47 | 3.99 | 15.46 | 10.32 | 1.99 | 5.33 | 10.45 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | 2.70 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $16M | $6M | $1M | $1M | $1M | $1M | $886430 | $886430 | $588148 | $588148 |
Binary clinical trial dependency
Based on reported figures, PolyPid's price-to-book ratio of 6.94 suggests that investors are pricing the firm primarily on its intellectual property and the potential of the PLEX platform rather than any tangible asset base, which is typical for pre-revenue biotech firms facing significant clinical trial uncertainty.
The valuation appears to be heavily discounted compared to peers like Halozyme, reflecting the market's skepticism regarding the company's ability to successfully navigate the SHIELD II trial. Investors should monitor whether this valuation gap narrows as the company approaches its next major data readout, which serves as the primary catalyst for any potential re-rating.
As reported in financial statements, the company's ROIC has remained deeply negative, with a volatile trend reaching -106.1% in 2025Q1, indicating that the firm is currently destroying invested capital as it funds non-discretionary R&D expenses without any offsetting commercial revenue or operational margin generation.
The erratic swings in ROIC are a direct consequence of the company's reliance on periodic equity financing to sustain its clinical development program. This trend suggests that until the PLEX platform achieves regulatory approval and commercialization, return metrics will remain fundamentally disconnected from traditional value creation benchmarks.
According to recent SEC filings, the company's current ratio has fluctuated significantly, dropping to 1.97 in 2025Q4, which highlights a narrowing liquidity buffer that may necessitate immediate capital market intervention to maintain ongoing clinical operations through the completion of the SHIELD II trial program.
The decline in the quick ratio suggests that the company's ability to cover short-term obligations is becoming increasingly sensitive to the timing of its next financing round. Investors should monitor the cash runway closely, as the current liquidity position appears insufficient to support long-term operations without further dilutive capital raises.
Based on the company's reported figures, the debt-to-equity ratio has shown extreme volatility, peaking at 102.65 in 2025Q1, which indicates that debt is being utilized as a stop-gap measure rather than a strategic tool for growth during periods of acute capital scarcity.
The interest coverage ratio of -355.42 in 2025Q4 underscores the firm's inability to service debt through operational earnings, confirming that all debt obligations are currently being met through external financing. This leverage profile warrants further investigation into the potential for future covenant risks if the company fails to secure non-dilutive funding.
As indicated by the provided financial data, the price-to-earnings ratio is fundamentally misapplied to PolyPid, as the company's negative TTM P/E of -2.23 fails to capture the binary nature of its clinical-stage business model and the significant option value inherent in its PLEX delivery platform.
Investors should instead focus on cash runway and clinical trial enrollment velocity, as these metrics provide a more accurate assessment of the company's survival and potential for future value creation. Relying on traditional earnings-based multiples in this context obscures the reality that the firm is currently a research-driven entity rather than a commercial enterprise.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PYPD stock.
PolyPid Ltd.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
PolyPid Ltd.'s return on equity (ROE) is -366.3%. The historical average is -144.2%.
Based on historical data, PolyPid Ltd. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.